Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxygen Biotherapeutics, which develops advanced oxygen-based therapies, has appointed Robert Diegelmann as the head of its new wound care division being established by the company.
Subscribe to our email newsletter
The new division’s first priority will be to develop over-the-counter wound treatment applications for Oxycyte. Oxycyte is the company’s perfluorocarbon therapeutic oxygen carrier.
Dr Diegelmann is a tenured professor of biochemistry and molecular biology, anatomy and emergency medicine at Virginia Commonwealth University Medical Center. He has worked with Oxycyte and understands its potential in wound care.
Chris Stern, chairman and CEO of Oxygen Biotherapeutics, said: “I view Bob Diegelmann as Virginia Commonwealth University’s wound care guru and I’m thrilled that he has contracted with us to be in charge of getting our topical and clinical wound indications to market.”